Europe · Wires & real time · Reuters Technology
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion
Detailed summary
Drugmaker Eli Lilly has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with Stipple Bio, the privately held biotech firm said on…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.reuters.com)
